Vaccine最新文献

{"title":"Trained immunity-based vaccines: A vision from the one health initiative","authors":"Miriam Angulo ,&nbsp;Carlos Angulo","doi":"10.1016/j.vaccine.2024.126505","DOIUrl":"10.1016/j.vaccine.2024.126505","url":null,"abstract":"<div><div>Trained immunity-based vaccines (TIbV or TRIMbV) represent a novel approach to combating infectious diseases. The innate immune system in animals, including humans, exhibits “memory-like” functions. Remarkably, the immunological mechanisms —both epigenetic and metabolic—) underlying this memory enables immune cells to develop defensive and protective outcomes against unspecific pathogenic infections. Under this context, the One Health initiative promotes integrative efforts to combat zoonotic (and anthropozoonotic) diseases, which is critical because 3 of 4 animal infections are transmitted to humans. Therefore, TIbV constitutes a potential affordable approach to control zoonotic pathologies, especially under pandemic scenarios. This review describes the state-of-the-art TIbV and their hurdles, opportunities, and prospects for the One Health initiative to prevent, control, and treat infectious diseases.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126505"},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose","authors":"James Peterson ,&nbsp;Daniel Drazan ,&nbsp;Beth Moughan ,&nbsp;Jason D. Maguire ,&nbsp;Lefteris Zolotas ,&nbsp;Roger Maansson ,&nbsp;Robert O'Neill ,&nbsp;Paula Peyrani ,&nbsp;Luis Jodar ,&nbsp;William C. Gruber ,&nbsp;Annaliesa S. Anderson ,&nbsp;Johannes Beeslaar","doi":"10.1016/j.vaccine.2024.126469","DOIUrl":"10.1016/j.vaccine.2024.126469","url":null,"abstract":"<div><h3>Background</h3><div>Vaccination against 5 prominent meningococcal serogroups (A/B/C/W/Y) is necessary for broad disease protection. We report immunopersistence through 4 years after a 2-dose (6-month interval) pentavalent MenABCWY primary vaccine series and safety and immunogenicity of a booster administered 4 years after primary vaccination.</div></div><div><h3>Methods</h3><div>This randomized, active-controlled, observer-blinded study was conducted in the United States and Europe. In stage 1, healthy MenACWY vaccine-naive or -experienced 10- to 25-year-olds were randomized 1:2 to receive MenABCWY and placebo or MenB-fHbp and MenACWY-CRM. Eligible participants were randomly selected to participate in stage 2, which was an open-label immunopersistence and booster extension. Immunogenicity was assessed through serum bactericidal antibody using human complement (hSBA) assays with serogroups A/C/W/Y (MenA/C/W/Y) and 4 primary serogroup B (MenB) test strains. Immunogenicity endpoints included hSBA seroprotection rates through 48 months after primary vaccination and 1 month after the booster. Safety endpoints included booster reactogenicity events and adverse events (AEs).</div></div><div><h3>Results</h3><div>Of 1379 eligible participants, 353 entered stage 2; 242 completed the 48-month blood draw after primary vaccination and 240 completed the booster vaccination phase. MenA/C/W/Y seroprotection rates remained high for 4 years following a 2-dose MenABCWY primary series (MenACWY-naive, 62.0 %–100.0 %; MenACWY-experienced, 98.7 %–100.0 %) and trended higher than those after a single MenACWY-CRM dose (MenACWY-naive, 38.1 %–95.2 %; MenACWY-experienced, 89.7 %–100.0 %). Corresponding seroprotection rates against MenB remained stable and generally higher than baseline (MenABCWY, 18.2 %–36.6 %; MenB-fHbp, 16.2 %–31.9 % across strains). Following a booster, seroprotection rates against all 5 serogroups were ≥ 93.8 % across groups. Most booster dose reactogenicity events were mild or moderate in severity, and AEs were infrequent.</div></div><div><h3>Conclusions</h3><div>Immune responses remained high for MenA/C/W/Y and above baseline for MenB through 4 years after the MenABCWY primary series, with robust responses for all 5 serogroups observed following a booster. The MenABCWY booster had an acceptable safety and tolerability profile consistent with the primary series. <span><span>NCT03135834</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126469"},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2","authors":"Erin Williams ,&nbsp;Felipe Echeverri Tribin ,&nbsp;Juan Manuel Carreño ,&nbsp;Florian Krammer ,&nbsp;Michael Hoffer ,&nbsp;Suresh Pallikkuth ,&nbsp;Savita Pahwa","doi":"10.1016/j.vaccine.2024.126484","DOIUrl":"10.1016/j.vaccine.2024.126484","url":null,"abstract":"<div><div>The severity of SARS-CoV-2 illness is influenced by factors including age, sex, pre-existing health conditions, and individual immune responses. However, the mechanisms conferring immunity following antigenic challenge have not been fully elucidated. There are currently no studies evaluating longitudinal proteomic changes in individuals following vaccination and breakthrough, limiting our understanding of the underlying mechanisms driving conferred immunity. In this work, we evaluated the differential protein expression in individuals with (CoV-P) or without (CoV-N) prior SARS-CoV-2 infection following primary vaccination and after breakthrough infection (CoV-BT). Overall, we found that individuals receiving primary vaccination relied on innate immune mechanisms, including complement and coagulation cascades, and natural killer cell-mediated cytotoxicity, while conversely, breakthrough infection immune mechanisms relied on T cell-mediated immunity. These mechanistic differences may help explain heterogeneity associated with vaccine-induced and breakthrough infection-related outcomes.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126484"},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016–2019","authors":"M. Haeberer ,&nbsp;A. López-Ibáñez de Aldecoa ,&nbsp;S. Seabroke ,&nbsp;J.L. Ramirez Agudelo ,&nbsp;L. Mora ,&nbsp;L. Sarabia ,&nbsp;E. Meroc ,&nbsp;Z. Aponte-Torres ,&nbsp;R. Sato ,&nbsp;A.W. Law","doi":"10.1016/j.vaccine.2024.126512","DOIUrl":"10.1016/j.vaccine.2024.126512","url":null,"abstract":"<div><div>This retrospective observational study aimed to quantify the costs associated with hospitalized respiratory syncytial virus (RSV) in children &lt;18 years admitted to the Spanish National Healthcare System between 2016 and 2019 and contrast them with the costs of unspecified bronchiolitis/bronchitis/pneumonia (UBP) and influenza. The mean cost per hospitalization episode was reported by age group, risk category and prematurity. Total annual hospitalization costs were calculated from population incidence rates and the mean cost per episode. A total of 41,934 children were hospitalized with RSV, 70,160 with UBP and 8525 with influenza during 2016–2019. The highest incidence of hospitalization for RSV, UBP, and influenza occurred among infants &lt;6 months. The mean cost per episode was highest for RSV cases aged &lt;6 months with at least one risk factor (€4760 high vs €2827 low risk), while the mean cost ranged from €3704–4352 for high-risk and €2687–3475 for low-risk children of other ages, and from €4300–44,594 for preterm infants. In the 0–5 months age group, the mean cost per episode for UBP was €4189 and €2666 for high and low risk, and for influenza it was €3134 and €2081, respectively; while the mean cost of co-infected RSV-influenza cases was €4809 and €2887, respectively. The mean total annual estimated cost for RSV for children aged 0–17 years was €39.3 M based only on reported cases, rising to €53.8 M if we correct for under-diagnosis and all RSV-attributable cases are considered. In contrast, the mean total annual cost for influenza was €5.9 M. Compared to influenza, RSV has a substantially higher economic burden; nevertheless, the Spanish immunization schedule recommends influenza vaccine between 6 and 59 months of age and RSV monoclonal antibody only for those aged &lt;6 months. RSV immunization is still to be implemented in older children, considering that 37 % of RSV hospitalized patients were aged ≥6 months.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126512"},"PeriodicalIF":4.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults","authors":"Yalin Deng ,&nbsp;Kaleen N. Hayes ,&nbsp;Yifan Zhao ,&nbsp;Preeti Chachlani ,&nbsp;Andrew R. Zullo ,&nbsp;Djeneba Audrey Djibo ,&nbsp;Cheryl N. McMahill-Walraven ,&nbsp;Vincent Mor ,&nbsp;Daniel A. Harris","doi":"10.1016/j.vaccine.2024.126501","DOIUrl":"10.1016/j.vaccine.2024.126501","url":null,"abstract":"<div><h3>Introduction</h3><div>Racial and ethnic disparities in COVID-19 vaccine access are well-documented; however, few studies have examined whether racial disparities are modified by other factors, including geographic location and area-level deprivation.</div></div><div><h3>Methods</h3><div>We conducted an observational study using the COVVAXAGE database. Medicare beneficiaries who received the COVID-19 vaccine primary series (two doses) between 01/01/2021 and 12/31/2021 were included. Racial differences in the time between doses was assessed by urbanicity using g-formula methods.</div></div><div><h3>Results</h3><div>We identified 11,924,990 beneficiaries (mean age = 75.4; 60 % female; 80 % White). Most beneficiaries (97.1 %) received their second vaccine on time. Delayed second doses were more common among beneficiaries who were Black (RR_delayed = 1.30, 95 %CI = 1.28–1.31) and rural (RR_delayed = 1.27, 95 %CI = 1.25–1.29) relative to White and urban beneficiaries. Racial disparities in delayed vaccinations varied in magnitude by degree of urbanicity.</div></div><div><h3>Conclusions</h3><div>Most beneficiaries received their second COVID-19 vaccine on time. Racial disparities were observed and shown to vary by geographic area.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126501"},"PeriodicalIF":4.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023","authors":"Nathaniel M. Lewis ,&nbsp;Elizabeth J. Harker ,&nbsp;Aleda Leis ,&nbsp;Yuwei Zhu ,&nbsp;H. Keipp Talbot ,&nbsp;Carlos G. Grijalva ,&nbsp;Natasha Halasa ,&nbsp;James D. Chappell ,&nbsp;Cassandra A. Johnson ,&nbsp;Todd W. Rice ,&nbsp;Jonathan D. Casey ,&nbsp;Adam S. Lauring ,&nbsp;Manjusha Gaglani ,&nbsp;Shekhar Ghamande ,&nbsp;Cristie Columbus ,&nbsp;Jay S. Steingrub ,&nbsp;Nathan I. Shapiro ,&nbsp;Abhijit Duggal ,&nbsp;Jamie Felzer ,&nbsp;Matthew E. Prekker ,&nbsp;Emily T. Martin","doi":"10.1016/j.vaccine.2024.126492","DOIUrl":"10.1016/j.vaccine.2024.126492","url":null,"abstract":"<div><h3>Background</h3><div>In test-negative studies of vaccine effectiveness (VE), including patients with co-circulating, vaccine-preventable, respiratory pathogens in the control group for the pathogen of interest can introduce a downward bias on VE estimates.</div></div><div><h3>Methods</h3><div>A multicenter sentinel surveillance network in the US prospectively enrolled adults hospitalized with acute respiratory illness from September 1, 2022–March 31, 2023. We evaluated bias in estimates of VE against influenza–associated and COVID-19–associated hospitalization based on: inclusion vs exclusion of patients with a co-circulating virus among VE controls; observance of VE against the co-circulating virus (rather than the virus of interest), unadjusted and adjusted for vaccination against the virus of interest; and observance of influenza or COVID-19 against a sham outcome of respiratory syncytial virus (RSV).</div></div><div><h3>Results</h3><div>Overall VE against influenza–associated hospitalizations was 6 percentage points lower when patients with COVID-19 were included in the control group, and overall VE against COVID-19–associated hospitalizations was 2 percentage points lower when patients with influenza were included in the control group. Analyses of VE against the co-circulating virus and against the sham outcome of RSV showed that downward bias was largely attributable the correlation of vaccination status across pathogens, but also potentially attributable to other sources of residual confounding in VE models.</div></div><div><h3>Conclusion</h3><div>Excluding cases of confounding respiratory pathogens from the control group in VE analysis for a pathogen of interest can reduce downward bias. This real-world analysis demonstrates that such exclusion is a helpful bias mitigation strategy, especially for measuring influenza VE, which included a high proportion of COVID-19 cases among controls.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126492"},"PeriodicalIF":4.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California","authors":"Chloe Le Marchand ,&nbsp;Jason Robert C. Singson ,&nbsp;Amy Clark ,&nbsp;Dhawani Shah ,&nbsp;Monice Wong ,&nbsp;Sebastian Chavez ,&nbsp;Marijoyce Naguit ,&nbsp;Lauren Nelson ,&nbsp;Hilary Rosen ,&nbsp;Seema Jain ,&nbsp;John J. Openshaw","doi":"10.1016/j.vaccine.2024.126499","DOIUrl":"10.1016/j.vaccine.2024.126499","url":null,"abstract":"<div><div>Multisystem inflammatory syndrome in children (MIS-C) is a rare condition occurring after SARS-CoV-2 infection in children under 21 years of age. Children (5–17 years) with MIS-C meeting the Centers for Disease Control (CDC) case definition were reported via California's passive disease surveillance system. Incidence of MIS-C was compared in unvaccinated and Pfizer-BioNTech vaccinated children aged 12–17 and 5–11 years. In the 12–17 year-old age group, there were 66 new cases among 872,936 unvaccinated children and 7 new cases among 2,117,575 vaccinated children. In the 5–11 year-old age group, there were 51 new cases among 2,113,725 unvaccinated children and 9 new cases among 1,221,293 vaccinated children. Compared with vaccinated children, the incident rate ratio of MIS-C was higher among unvaccinated children in both the 12–17-year-old group (22.9, 95 % confidence interval [CI]: 10.5–49.8, <em>p</em> &lt; 0.0001) and the 5–11-year-old group (3.3, 95 % CI: 1.6–6.7, <em>p</em> = 0.0004). While MIS-C is rare, our results suggest that vaccination with the Pfizer-BioNTech vaccine is protective against MIS-C.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126499"},"PeriodicalIF":4.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic","authors":"Maryke S. Steffens ,&nbsp;Katarzyna T. Bolsewicz ,&nbsp;Catherine King ,&nbsp;Bianca Bullivant ,&nbsp;Ikram Abdi ,&nbsp;Frank Beard","doi":"10.1016/j.vaccine.2024.126498","DOIUrl":"10.1016/j.vaccine.2024.126498","url":null,"abstract":"<div><h3>Purpose</h3><div>In Australia, adolescents are scheduled to receive vaccinations against diphtheria, tetanus, pertussis, human papillomavirus, and meningococcal disease, delivered via school vaccination programs and general practitioners (GPs). Public health measures implemented in response to the COVID-19 pandemic impacted uptake of some adolescent age-based vaccinations. Limited information is available on parents' approaches to vaccinating their adolescent children during the pandemic. We aimed to explore parents' experiences of adolescent age-based vaccinations during the pandemic, and factors they perceived as hindering or facilitating vaccination.</div></div><div><h3>Methods</h3><div>In July 2022 we recruited 21 Australian parents of adolescent children eligible for age-based vaccinations in 2021. We recruited from metropolitan and regional settings, and from states where uptake was most and least affected by pandemic disruptions. We conducted 30-min virtual or phone interviews and analysed the data thematically.</div></div><div><h3>Results</h3><div>Parents described how experiences before and during the COVID-19 pandemic influenced their perspectives on and experiences with adolescent age-based vaccinations. Motivation to vaccinate their children was informed by personal beliefs and experiences with the healthcare system. Parents described practical issues, including ease of access to the school vaccination program or a GP, and knowledge about vaccination schedules and services. Parents suggested enhancing promotion of adolescent vaccination benefits and information sharing, and recommended improving access to vaccination services outside the school program.</div></div><div><h3>Discussion</h3><div>Findings have potential to improve delivery of adolescent age-based vaccinations, including during future pandemics. While this study was conducted in the Australian context, findings and recommendations have relevance to overseas adolescent age-based vaccination programs.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126498"},"PeriodicalIF":4.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study","authors":"Sung-a Kim ,&nbsp;Megumi Maeda ,&nbsp;Fumiko Murata ,&nbsp;Haruhisa Fukuda","doi":"10.1016/j.vaccine.2024.126497","DOIUrl":"10.1016/j.vaccine.2024.126497","url":null,"abstract":"<div><h3>Introduction</h3><div>Post-COVID-19 conditions have emerged as a global health challenge. This study examined the long-term effects of COVID-19 vaccination on the incidence and risk of post-COVID-19 conditions in Japan.</div></div><div><h3>Methods</h3><div>This retrospective cohort study was conducted using a database comprising medical claims, COVID-19 case information, and vaccination records of persons residing in four Japanese municipalities. The cohort included COVID-19 cases diagnosed between August 2020 and December 2022. Participants were classified according to the duration between their most recent COVID-19 vaccination and COVID-19 occurrence (≥365 days, 150–364 days, and 14–149 days). The incidences of 36 post-COVID-19 conditions were monitored for 3, 5, and 8 months after infection. Cox proportional hazards models were used to calculate the risk of developing each post-COVID-19 condition within 8 months after infection according to vaccination status.</div></div><div><h3>Results</h3><div>From among 84,464 participants, 9642 (11.4 %) developed post-COVID-19 conditions over 8 months. The 8-month risks of developing 28 (including various respiratory conditions, cardiovascular conditions, inflammatory and immune diseases, physical conditions, psychiatric conditions, and endocrine disorders) of the 36 target conditions were significantly lower when individuals had been recently vaccinated (14–149 days) before infection.</div></div><div><h3>Conclusions</h3><div>COVID-19 vaccination can reduce the incidence and risk of post-COVID-19 conditions if administered within 5 months before infection. Despite having the highest mean age and prevalence of comorbidities, individuals who were most recently vaccinated had a lower risk of developing post-COVID-19 conditions. These results provide important evidence for future COVID-19 vaccination strategies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126497"},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices","authors":"K. Delaruelle ,&nbsp;E. Lermytte ,&nbsp;M. Bockstal ,&nbsp;P. Vuolanto ,&nbsp;P. Bracke","doi":"10.1016/j.vaccine.2024.126485","DOIUrl":"10.1016/j.vaccine.2024.126485","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic underscored the issue of vaccine hesitancy, leading researchers to study the determinants of people's willingness to receive the COVID-19 vaccine. This study is the first to comprehensively investigate the role of preventive practices at both the individual and contextual level, drawing on the theoretical concept of “cultural health capital”.</div></div><div><h3>Methods</h3><div>Utilizing data from the Survey of Health, Ageing, and Retirement (SHARE), covering information from 18,454 individuals aged 50 years and above residing in 25 European countries, we examined the influence of past engagement in preventive practices and the prevalence of such practices within a country on the likelihood of COVID-19 vaccine uptake. Our analysis included (i) previous vaccination behaviors, (ii) other healthcare-related behaviors, and (iii) lifestyle factors at both the individual and contextual levels. Leveraging the longitudinal design of the SHARE, we accounted for the temporal ordering of the relationships.</div></div><div><h3>Results</h3><div>At the individual level, almost all preventive behaviors were significantly related to people's willingness to receive the COVID-19 vaccine. Individuals who (i) had received an influenza vaccination prior to the COVID-19 outbreak and during childhood, (ii) had regularly participated in dental and blood pressure check-ups throughout their lives, and (iii) did not engage in lifestyle-related risk behaviors, were more likely to accept the COVID-19 vaccine. Notably, alcohol use was not significantly associated. At the contextual level, only the vaccination coverage rate for influenza was found to be robustly related, indicating that individuals were more inclined to receive the COVID-19 vaccine in countries with higher influenza vaccination rates prior to the pandemic.</div></div><div><h3>Conclusion</h3><div>Active participation in preventive practices and effective implementation of vaccination campaigns can contribute to the development of (institutional) cultural health capital, which ultimately promotes a greater willingness to get vaccinated against COVID-19.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126485"},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}